Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1493
  • Home
  • Print this page
  • Email this page
Year : 2014  |  Volume : 62  |  Issue : 1  |  Page : 74-81

Cytokines and Biologics in non-infectious autoimmune uveitis: Bench to Bedside

1 National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; Translational Vision Research Laboratory, University College London, London, UK
2 Singapore National Eye Centre, Singapore
3 Singapore Immunology Network, A*Star, Singapore
4 Translational Vision Research Laboratory, University College London, London, UK
5 National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore

Correspondence Address:
Rupesh Agrawal
Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 308433 Singapore

Login to access the Email id

Source of Support: Dr Rupesh Agrawal is funded by National Medical Research Council (Singapore) Overseas research training fellowship at University College London & Moorfi elds Eye Hospital., Conflict of Interest: None

DOI: 10.4103/0301-4738.126187

Rights and Permissions

Intraocular inflammatory eye disease is one of the important causes of ocular morbidity. Even though the prevalence of uveitis is less common in relation to diabetic retinopathy, glaucoma or age related macular degeneration, the complexity and heterogeneity of the disease makes it more unique. Putative uveitogenic retinal antigens incite innate immunity by the process of antigen mimicry and have been shown to be associated in patients with intraocular inflammatory disease by numerous experimental studies. Laboratory diagnostic tools to aid the etiologic association in intraocular inflammatory disease have evolved over the last two decades and we are entering into an era of molecular diagnostic tests. Sophisticated novel technologies such as multiplex bead assays to assess biological signatures have revolutionized the management of complex refractory uveitis. Nevertheless, there is still a long way to go to establish the causal relationship between these biomarkers and specific uveitic entities. Experimental studies have shown the supreme role of infliximab in the management of Behcet's disease. Despite significant experimental and case control studies, the deficiency of randomized clinical trials using these biologic agents has handicapped us in exploring them as a front line therapy in severe refractory uveitis. Studies still need to answer the safety of these potentially life threatening drugs in a selected group of patients and determine when to commence and for how long the treatment has to be given. This review article covers some basic concepts of cytokines in uveitis and their potential application for therapy in refractory uveitis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded471    
    Comments [Add]    
    Cited by others 2    

Recommend this journal